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ABSTRACT
DEVELOPING A MORE CLINICALLY-RELEVANT MOUSE MODEL OF
CISPLATIN NEPHROTOXICITY
Cierra N. Sharp
April 25, 2016
Cisplatin is a nephrotoxic chemotherapeutic that causes acute kidney
injury (AKI) in 30% of patients. Although recovery can occur after one episode of
cisplatin-induced AKI, studies have indicated multiple episodes may lead to the
development of chronic kidney disease (CKD), an irreversible disease with no
current treatments. The standard mouse model of cisplatin-induced AKI consists
of one, high dose of cisplatin (> 20 mg/kg) that is lethal to the animal three days
later. This model doesn’t accurately reflect the repeated dosing regimen patients
receive, and doesn’t allow for long-term outcome studies of pathologies
associated with CKD. We have developed a repeated dosing model of cisplatin
(7mg/kg once a week for four weeks). This model allows for the long-term
survival of mice, and the associated pathology is fibrosis-the hallmark of CKD.
Thus, data indicate that the repeated dosing model can be used to study AKI to
CKD progression.
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INTRODUCTION
Acute kidney injury (AKI) is defined as a rapid loss in renal function
accompanied by accumulation of waste products, such as urea and creatinine, in
the blood. According to RIFLE criteria, which aims to standardize the definition
of AKI, AKI is associated with a 50% loss in glomerular filtration rate (GFR), a
doubling in serum creatinine (SCr) levels, and a significant decrease in total urine
output (1, 2). Presently, the mortality rate of patients with AKI is 50%, and having
AKI increases a hospital patient’s risk of death 10-15fold (3, 4).
Cisplatin is a potent chemotherapeutic for the treatment of many solid
tumor cancers, including ovarian, testicular, head and neck, and lung cancers (5,
6). While the potency of cisplatin makes it an excellent chemotherapeutic choice,
there are very serious side effects associated with this drug. These include bone
marrow suppression, ototoxicity, neurotoxicity, and nephrotoxicity (7). Of these,
the risk of developing cisplatin-induced nephrotoxicity leading to AKI is high.
After a single dose of cisplatin, 33% of patients will develop nephrotoxicity.
Furthermore, cisplatin-induced AKI accounts for 19% of all cases of AKI, making
it a prominent health problem (8).
The high relevance of cisplatin-induced nephrotoxicity can be explained by
the ready uptake of cisplatin in the blood and kidney. The kidney contains
glomeruli cells which can freely filter blood, and, as a result, cisplatin is also
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freely filtered. Once cisplatin is filtered through glomeruli, it is taken up by Ctr1
and OCT2 transporters in an energy-dependent driven manner (9-11) . These
transporters are responsible for secretion and absorption of organic molecules.
Once cisplatin is transported into proximal tubule cells, it is readily
converted to a highly reactive metabolite and is conjugated to glutathione,
proteins, RNA, and DNA (5, 12, 13). Cisplatin causes cross-linking of DNA
strands, thereby inhibiting DNA replication and gene transcription (6, 12, 13). In
the context of cancer, this is therapeutic as it leads to inhibition of growth,
senescence, and cell death (6). However, in the proximal tubule cells, cisplatin
accumulates to amounts 5 times higher than that in the serum, and thus these
processes are extremely detrimental as they lead to severe proximal tubule cell
death, ultimately resulting in kidney injury and subsequent loss of function (6,
14).
Cisplatin leads to two forms of cell death in proximal tubule cellsapoptosis and necrosis (7). It has been well documented that cisplatin activates
the intrinsic apoptotic cell death pathway(15). This involves the accumulation of
Bax, a BCL2 pro-apoptotic family member protein, in the mitochondria (16). This
accumulation leads to the release of cytochrome c from the mitochondria and
eventual activation of initiator and effector caspases. This apoptotic pathway
plays a pivotal role in cisplatin-induced AKI pathophysiology, as Bax-/- mice are
resistant to cisplatin nephrotoxicity (17).
Other BCL2 pro-apoptotic family members (such as PUMA-α) can be
activated by p53,a tumor suppressor that is activated by DNA damage or
2

genotoxic stress (7, 18). Activation of p53 can result in the increased
transcription of these pro-apoptotic proteins. Furthermore, p53 can act directly
on BCL-2 proapoptotic family members to lead to the release of cytochrome c
(18). Through these mechanisms, p53 plays a pivotal role in apoptosis, both in
terms of killing cancer, and also as a mechanism of cisplatin-induced
nephrotoxicity.
While apoptosis is predominately found in animal models of AKI, the main
pathology associated with this human AKI is acute tubular necrosis (19, 20).
Acute tubular necrosis is sudden death of the tubular epithelial cells that
compromise the renal tubules, including both proximal and distal tubule cells(19).
This pathology is seen in both animal and humans who have experienced AKI,
and is often classified as acute tubular necrosis based on death to the distal
tubules (which are affected to a greater extent than proximal tubules) and loss of
brush borders (20). This pathology occurs to a greater extent in animal models
of AKI than in humans. This is due to the fact that the level of injury patients
endure is less than the level of injury achieved in animal models used to study
AKI. Studies performed to examine AKI using nephrotoxins lead to very high
levels of acute tubular necrosis due to that fact that the dose of the toxin being
used is extremely high (20). It has also been suggested that this discrepancy in
human and animal pathology may be due to the fact that human kidney biopsies
are rarely performed, and when they are, they usually do not sample the outer
medulla where the tubules are located (21). Furthermore, if biopsies are done, it
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is usually during the recovery phase after AKI, and thus levels of necrosis do not
accurately reflect levels that would be seen during injury phase (21).
The pathophysiology of cisplatin-induced AKI not only involves tubule cell
death, but also several other processes. Of importance are the involvement of
the cell cycle and immune cell infiltration/inflammatory pathways (7, 15). The cell
cycle is a complex system of checks and balances to ensure that cell proliferation
occurs without fault. Proliferation is a vital process in the kidney after injury, as
remaining epithelial cells will dedifferentiate and proliferate to replace damaged
tubular epithelial cells- an important step in adaptive recovery after AKI (21).
The ability of the cell cycle to proceed from G1 to S, S to M, and M to G2
phase in a subsequent order necessary for proper cell proliferation is controlled
by cyclins (22). Cyclins are periodically synthesized and degraded during the cell
cycle, and this leads to unidirectional progression of the cell cycle. Cyclins have
been found to form heterodimers with Cdk subunits. Cdk subunits are
serine/threonine protein kinases that are only active when bound to cyclins.
Once cyclins binds, cdk subunits take on basal kinase activity. This kinase
activity drives the progression of the cell cycle from one phase to another (22).
While cyclins and their heterodimerization with Cdks are the main drivers
of cell cycle progression, there are also protein effectors that serve as
checkpoints to ensure that each part of the cell cycle is completed successfully,
further ensuring that the cell cycle proceeds without fault (22). These effectors
monitor DNA damage, incomplete DNA synthesis, and whether or not mitosis is
completed successfully. These effectors primarily control the entry of cells into
4

both S and M phases by inhibiting or stimulating kinase activity of Cdks (22). In
humans, there are two families of protein effectors- the CDK interacting protein/
kinase inhibitory protein (CIP/KIP) family and the inhibitor of cyclin-dependent
kinase 4 (INK4) family (23). Within the CIP/KIP family, p21 has been indicated
as a potential therapeutic target for cisplatin-induced AKI.
p21 is expressed constitutively at low levels in the cell. Overexpression of
p21, which can be induced by p53-dependent or independent mechanisms, leads
to cyclin kinase inhibition and induction of senescence (24, 25). p21 has been
found to play a major role in cisplatin-induced AKI, as it determines whether or
not tubular cells undergo cell death or survive (24). Upon injury by cisplatin,
many quiescent cells enter into the cell cycle as evidenced by increased PCNA
staining and BrdU incorporation, and there is a marked induction of p21 (24).
Higher levels of p21 are concentrated in the nuclei of distal and proximal tubule
cells upon cisplatin injury (22).
While the mechanism of p21 protection is not fully understood, its role in
regulation of the cell cycle may be key in repairing and regenerating injured cells
(22, 24). Studies using p21 -/- mice have indicated that acute kidney injuryassociated loss of function is exacerbated and worsened following cisplatin
administration when compared to wild-type mice (26). Morphologically, cisplatininduced AKI damage is restricted to the distal and proximal tubules. However,
the damage in knockout mice was present throughout the entire kidney cortex,
and apoptosis was also more widespread in these mice (22). Furthermore, there
was an increase in nuclear size due to polyploid content of proximal tubule cells
5

as the result of an uncoordinated cell cycle, thus indicating the importance of p21
mediating AKI through cell cycle progression control. Furthermore, studies have
also shown that when both p21 and 14-3-3σ (another cell cycle inhibitor protein)
are expressed together, cell cycle progression is inhibited, resulting in repair of
damaged cells and subsequent regeneration of healthy epithelial cells(27).
Animal knockout studies have been supplemented with in vitro studies.
p21 overexpression in mouse proximal tubular cells instilled cytoprotective
effects (27). Increasing levels of p21 expression as a potential renoprotective
therapy has also been reported using prior administration of an adenovirus vector
directing the overexpression of p21 (27). These studies indicate that p21 has
renoprotective effects in cisplatin-induced AKI.
Taken together, these data suggests that upon initial cell stress,
quiescent cells enter into the cell cycle and cell cycle inhibitors such as p21 and
14-3-3σ are induced to check the cycle at both G1 and G2 phases(27). Both p21
and 14-3-3σ are needed to successfully coordinate the cell cycle so that injury to
the cell can be properly repaired, and this in turn leads to repair and regeneration
of renal cells after acute injury (27).
Most research on cyclin-dependent kinase inhibitors has focused mainly
on the CIP/KIP family, especially p21. Little is known about the INK4 family, but
recent studies have shown that p18 is important. p18 interacts with CDK4/6 and
inhibits the cell cycle in early G1 phase (28). Studies using p18 -/- mice have
shown, over a course of 28 days, p18 -/- mice have significantly worse survival
(28). Furthermore, these mice showed increased markers of endoplasmic
6

reticulum stress (ER stress), and worse injury morphology. Taken together these
data indicate that cisplatin-induced AKI was aggravated in p18 -/- mice, and that
p18 may play a role in protecting the kidney by interaction with ER stress cell
death pathways (28). This was confirmed in studies with p18 overexpressing
LLC-PK1 renal tubular epithelial cells. Overexpression of p18 in these cells
inhibited the cell cycle in the G1 phase, and this was associated with a decrease
in apoptosis levels (29). Commonly, the ER stress pathway promotes cell
survival, but in times of prolonged stress (as associated with AKI), the ERS
pathway favors apoptosis. Thus, it was concluded that p18 protects from
cisplatin-induced AKI by inhibiting the ER stress pathway and therefore apoptosis
(29).
Activation of inflammatory pathways and immune cell infiltration are also
involved in cisplatin-induced AKI. After an acute injury, injured resident kidney
cells release tumor necrosis factor α (TNFα) which serves as a chemoattractant
to recruit immune cell types, mainly neutrophils to the site of injury in the kidney
(30). Once recruited, neutrophils can initiate the activation of the downstream
immune system. Once this activation occurs, M1 subtype macrophages eat
dead proximal tubule cells and neutrophils (31). It has been shown that
recruitment of this type of macrophages amplifies initial injury in the kidney (21).
While neutrophils and macrophages are involved in the initial inflammatory
response after injury, many other immune cell types have been reported as
mediators of cisplatin-induced AKI. Of importance are CD4+ cytotoxic T cells,
CD4+CD25+ T regulatory cells, and dendritic cells(15). Of these cells types, the
7

role of CD4+ cytotoxic T cells has been well characterized. Mice depleted of
CD4+ cytotoxic T cells had better renal function and less injury when treated with
cisplatin and when these mice had their CD4+ cytotoxic T cell levels restored,
renal function decreased and injury worsened(32). This may have been due to
the fact that these cells produce FasL and Tim-1 which are important for T-cell
mediated cytotoxicity, leading to the death of proximal tubule cells (32).
Whereas CD4+ cytotoxic T cells are detrimental in AKI, CD4+ CD25+ T
regulatory cells are protective. These cells play a role in innate immune
suppression as well as suppression of CD4+ T cell –mediated cytotoxicity (33).
In animal studies where T regulatory cells were depleted, AKI was worsened
(34).
Dendritic cells are anti-inflammatory as evidenced by their production of
IL-10, an anti-inflammatory cytokine (35). Furthermore, dendritic cells can induce
T regulatory cells, suggesting that they are protective in cisplatin-induced AKI
(36). This is in fact the case- depletion of dendritic cells resulted in decreased
renal function, increased tubular injury, and higher mortality rates when mice
were treated with cisplatin (37).
Taken together, previous studies suggest that AKI is marked by a very
complex mechanism of injury. In addition to cell death, cell cycle arrest, and
immune cell infiltration, AKI pathophysiology also includes oxidative stress as
mediated by mitochondrial dysfunction, glutathione depletion and inactivation,
and endothelial cell dysfunction (7, 15).
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Most of what is known about cisplatin-induced AKI pathology exists
because we are able to study these processes in mouse models of AKI. As a
result, studies for the development of therapies for protection against AKI and
reversing injury as the result of AKI have also been performed in animal models.
Unfortunately, while there have been many experimental therapies developed for
the treatment of cisplatin-induced AKI, none have made it past clinical trials (7,
15). Currently, only palliative care therapies exist for severe, sustained AKI (1, 3,
4). In order to prevent cisplatin-induced AKI in patients, several precautions are
taken. When possible, lower doses of cisplatin are used in conjunction with
newer, less toxic chemotherapeutics to minimize cisplatin nephrotoxicity while
maintaining its therapeutic efficacy(38). However, this type of dosing regimen is
usually only used for palliative care. In instances where cisplatin can be used to
cure cancer, particularly in the case of germ cell line cancers, a high dose of
cisplatin administered over a short period of time is still used, putting these
patients at the highest risk for developing AKI (38). Currently, the standard
preventative measure for cisplatin nephrotoxicity and subsequent AKI is
intravaneous saline infusions given before cisplatin administration. Saline
induces diuresis, and by doing so, lowers overall nephrotoxicity, but the
mechanism by which saline is preventative is not well-defined (38).
Alternatively, the administration of less nephrotoxic platinum drugs may be
given to patients who run a high risk of developing AKI. Of the platinum
alternatives, carboplatin is commonly used. Carboplatin was designed
specifically to reduce the side effects of cisplatin (39, 40). Unfortunately,
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carboplatin can still have nephrotoxic side effects, especially in patients who
have previously received cisplatin and have increased nephrotoxicity sensitivity
(41). Furthermore, cisplatin is still the better of drug of choice for most cancers
due to its higher potency (39).
An alternative to creating a new, less nephrotoxic platinum
chemotherapeutic would be to design a drug that could be used to protect the
kidney from injury during the course of cisplatin treatment. This would not only
avoid the development of AKI, but also allow for higher doses of cisplatin to be
administered, which would make for a more efficacious cancer treatment option.
Unfortunately, there is only one renoprotective agent available for cisplatininduced AKI, and it is no longer used clinically for this purpose (42). In the early
2000’s, amifostine was FDA-approved to be used as a renoprotective agent with
cisplatin treatment of ovarian cancer (43). In a Phase III clinical trial of women
with ovarian cancer, amifostine lowered the risk of nephrotoxicity from 33% to
10% overall, and the percentage of patients that required a delay in the next
treatment or discontinuation of treatment altogether due to nephrotoxicity
decreased from 36% to 10% (43, 44).
High doses can be given due to amifostine’s mechanism of action, thereby
increasing its efficacy as a renoprotective agent. Amifostine is rapidly converted
to an active thiol metabolite via dephosphorylation by alkaline phosphatase. This
thiol metabolite is preferentially taken up by normal tissue (42). Once uptake
occurs, this active thiol metabolite scavenges for free radicals and depletes them.
At the same time, it can also bind directly to cytotoxic drug molecules to
10

inactivate them (42). Furthermore, amifostine has few side effects, most of which
are reversible and manageable. The most serious side effects include transient
hypotension, allergic skin reactions, and severe nausea(42). Most importantly,
amifostine doesn’t attenuate the efficacy of chemotherapeutics. In fact, preclinical studies have suggested that amifostine may protect against the
development of secondary malignancies associated with chemotherapeutic
treatment (42)
While extensive pharmacokinetics have been studied in mice, little is
known about the pharmacokinetics of amifostine in humans. Most clinical trials
done with amifostine and cisplatin use a single, high dose of amifostine given
before a single dose of cisplatin (38). Furthermore, the dose of cisplatin used is
usually very high. Currently, most cisplatin regimens consist of lower doses of
the drug given over an extended period of time, or in multiple doses to curtail
nephrotoxic side effects. Thus the efficacy of amifostine with these newer low
dosing regimens has yet to be elucidated. Case studies have reported that
amifostine given before treatment of ovarian cancer with cisplatin and etoposide
can lead to severe nephrotoxicity, ototoxicity, and neurotoxicity(45). Due to lack
of renoprotective and injury ameliorating therapeutics available, nephrotoxicity of
cisplatin must be monitored closely. This is done by extensively measuring
changes in kidney function. Clinically, the golden standard is measurements of
GFR and changes in serum creatinine (46-49). Serum creatinine is used as an
indirect measure of GFR, as a doubling in serum creatinine equates a 50%
decrease in GFR (loss of kidney function). Unfortunately, measuring serum
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creatinine levels is an insensitive and faulty assay(49). Changes in serum
creatinine usually are not detectable until there is 50% nephron loss. At this
point, the level of AKI sustained is very high and may not be reversible.
Furthermore, serum creatinine levels can be altered by levels of protein uptake
and changes in protein in catabolism (47-49). This is due to the fact that
creatinine is the byproduct of creatine breakdown from muscle catabolism. Thus,
basal serum creatinine levels differ based on age and weight (47-49). These
factors may falsely represent a full recovery from AKI, but rather suggest that
there is injury/ change in kidney function, but that it is undetectable by this
method.
This may be key in explaining why, even in patients with one instance of
AKI in their lifetime, there is increased susceptibility to developing chronic kidney
disease later in life (50-52). There are approximately 600,000 new cases of AKI
each year, and it has been suggested that 20% of these cases go on to develop
CKD (51, 53). This 20% accounts for patients who sustain severe AKI requiring
dialysis and are able to recover. Patients who receive an acute tubular necrosis
diagnosis go on to develop CKD 18-24 months later (50). This is surprising as it
was formerly believed that patients who recovered from AKI had generally good
renal outcomes. However, studies on AKI recovery used the development of
end-stage renal disease to define a poor renal outcome. Studies including the
progression of AKI to CKD indicate that the poor prognosis rate of patients who
“recover” from AKI is actually greater than expected (50). Furthermore, the
likelihood of developing CKD is also associated with the number of times a
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person sustains AKI in their life (54). Thus, there is a need to monitor kidney
function even after recovery.
Chronic disease kidney refers to a kidney disorder of varying severity, and
thus affects many people (55). Chronic kidney disease is a progressive disease,
and the early stages are often asymptomatic and reversible. However, the
problem with chronic kidney disease arises from the worsening of the disease
over the period of many decades (55). As a result, it is obvious that chronic
kidney disease is often associated with aging (56). This is in part due to the fact
that in older populations, there is an increased prevalence of diabetes and
hypertension (56). These comorbidities worsen chronic kidney disease.
Ultimately, a patient who has chronic kidney disease and one or more
comorbidities are more likely to progress from chronic kidney disease to endstage renal disease (55). Much like AKI, there are currently no therapies to
ameliorate chronic kidney disease or halt progression to end stage renal disease.
As a result, most patients will be placed on dialysis, which is costly and is often
not that useful. Eventually, the kidney failure worsens, leading to high rates of
mortality. There are approximately 400 per million people deaths in the U.S.
from chronic kidney disease alone (55).
Clinically, CKD is defined as the presence of kidney damage, particularly
albuminuria and proteinuria, and decreased kidney function as measured by
serum creatinine levels for a period of three months or more (55). The severity of
this disease is classified based on the total loss of GFR, as is the case for AKI as
well. The pathology of chronic kidney disease differs from that of AKI. Whereas
13

proximal tubule cells are the source of most damage in AKI, glomeruloclerosis
and nephrosclerosis are commonly associated with chronic kidney disease (55).
Furthermore, chronic kidney disease is marked by an increase in interstitial
kidney fibrosis. Fibrosis is the hallmark of CKD, and is characterized by the
pathological deposition of excessive extracellular matrix (57). This matrix is
often rich in collagens type I and III, as well as fibronectin (58, 59). In the
presence of fibrosis, tubule cells cannot secrete toxins or receive nutrients from
circulation due to the separation from peritubular capillaries by fibrosis (57). The
processes that underlie fibrosis are similar to those that occur in normal wound
healing. Whereas in wound healing myofibroblasts play a beneficial role, the
persistence of this cell type results in detrimental processes indicative of
fibrogenesis (57).
Myofibroblasts are the cell type most responsible for the production of
cytokines and chemokines leading to increase deposition of extracellular matrix
proteins, particularly collagens (57). Under normal conditions, myofibroblasts are
not detectable in the kidney. During pathogenic processes, these myofibroblasts
are found to increase greatly in number and are found usually in the interstitium
and around injured glomeruli, where fibrosis most commonly occurs (57). The
source of these myofibroblasts is still a matter of debate. Intricate fate-mapping
studies have shown that a small percentage of myofibroblasts arise from resident
fibroblasts in the kidney, while most are derived from pericytes (57) .
Immune cells, particularly macrophages, play a pivotal role in resolving
fibrogenesis. This is due to the fact that macrophages are able to internalize
14

collagen and degrade it with MMPs (60) . Once degraded, collagen can then be
further destroyed by cathepsins and lysosomes (60). In doing so, these
macrophages can ameliorate low levels of fibrosis. Currently, available animal
models to study chronic kidney disease focus on this fibrotic aspect and
developing therapies to ameliorate fibrosis. These models include the UUO, IR,
and folic acid models (61).
As previously discussed, AKI is associated with an increased likelihood of
developing chronic kidney disease based on severity and the number of AKI
occurrences (50). However, recent studies have suggested that AKI can
progress to CKD, and that AKI and CKD are interconnected syndromes (62).
The process by which this AKI to CKD transition occurs is very complex, but
focuses on the underlying mechanism of maladaptive repair. To understand the
processes that occur during maladaptive repair, it is first important to understand
the processes involved in adaptive repair.
After AKI, neutrophils are responsible for the activation of the immune
system and recruit M1 type macrophages to the site of injury (15, 21). While M1
macrophages have been associated with worsening of injury, M1 macrophages
quickly take on a M2 phenotype, which is essential for adaptive repair (63, 64).
These M2 macrophages remove cellular debris and secrete TGFβ, fibronectin,
and other growth factors that are essential for supporting the growth of new
epithelial cells to replace those that have undergone apoptosis or necrosis (63,
64). The source of these new epithelial cells has been extensively studied, and
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data suggest that these cells arise from existing epithelial cells which are able to
dedifferentiate and proliferate to replace lost cells (21, 57).
There are several overlapping processes that define adaptive and
maladaptive repair. The true difference between these forms of repair depends
on whether or not the injury is singular (as is often the case with AKI), or if it is
recurrent. Grgic et al. developed a Six2-Cre-LoxP technology to selectively
express the diphtheria toxin receptor in proximal tubule cells (65). Using this
model, they showed that a tubule cells are able to repair injury from a single dose
of diphtheria toxin (65). However, after three doses of the toxin, persistent
inflammation ensued, leading to increased levels of TGFβ1, collagen Type 1a1
(col1a1), and fibronectin (65). This ultimately resulted in progressive
fibrogenesis and secondary glomerulosclerosis, indicative of CKD (65).
To better understand the processes occurring with recurrent injury,
maladaptive repair in terms of both the cell cycle of tubular epithelial cells and the
role of immune cells, particularly macrophages, has been extensively studied in
the context of CKD. In several models of CKD, it has been shown that cells often
become senescent, and Grgic et al. have hypothesized that senescence may
play a pivotal role in maladaptive repair associated with recurrent injury (65).
Senescence is a detrimental process for two reasons. For one, senescent cells
will remain present in the kidney and cannot be cleared by recruited
macrophages. Thus, they cannot be replaced with new epithelial cells.
Ultimately, this results in a decline in kidney function that is permanent.
Secondly, even in this senescent state, epithelial cells continue to produce pro16

fibrotic factors, thus increasing fibrogenesis (21, 66). Yang et al. demonstrated
that this senescent state was the result of G2/M cell cycle arrest in these
epithelial cells (66).
Furthermore, it has been shown that recruited M1 macrophages are
unable to undergo the switch to M2 type macrophages, thereby leading to
maladaptive repair and worsened injury (67). While M2 subtype macrophages
are regarded as protective against maladaptive repair, recent studies have
suggested that M2 macrophages can also be key in fibrogenesis (68). When
present at high levels in a unilateral ureteral obstruction model, M2 macrophages
produce large amounts of TGFβ, which is an inducer of fibrotic pathways (68).
When M2 macrophages were depleted in this model, fibrosis was ameliorated
(68). Ultimately, maladaptive repair mechanisms are associated with recurrent,
persistent injury and models of CKD. Of maladaptive repair mechanisms, cell
cycle arrest and the role of both M1 and M2 macrophages have been shown to
play a role in kidney fibrosis.
With the increasing prevalence of CKD and more studies are emerging on
the importance of the AKI to CKD transition/ recurrent injury, it is important to have
animal models that can be used to recapitulate the process by which this happens.
This is especially true for cisplatin-induced AKI, as approximately 10-20% of all
cancer patients will receive cisplatin alone or in combination therapy, and 33% of
these run the risk of developing AKI. Furthermore, most of what is known about
maladaptive repair involved in AKI to CKD transition has been studied in
ischemia/reperfusion models of AKI.

Unfortunately, no such models exist for
17

cisplatin-induced AKI leading to CKD.

Furthermore, the standard model of

cisplatin-induced AKI does not recapitulate the type of treatment regimen patients
receive and does not allow for long-term studies. With the standard model of AKI,
mice are administered a single, high dose of cisplatin (>20 mg/kg). This dose is
lethal to the mouse beyond 72 hours, and thus examining the AKI to CKD
transition, a process that may take place over several decades in humans, is not
possible. Furthermore, humans receive multiple low doses of cisplatin. This is
done to decrease the likelihood of AKI while maintaining a dose that is efficacious
for the treatment of the cancer.
Thus, we have developed a low dose, repeated dosing model of cisplatin
induced kidney injury that both recapitulates the type of dosing regimen patients
receive, as well as allows for long-term analyses of what happens to the kidneys
post-AKI. We have found that with this model, processes indicative of AKI such
as high levels of cell death do not occur, but that the ultimate pathological outcome
is fibrosis. Thus, this model can be used to examine the transition from AKI to
CKD in a mechanistic way.

In doing so, this will provide insight into when

maladaptive repair occurs temporally and if processes that occur in this model are
similar to those seen in models of CKD. By understanding more about what
happens in this transition mechanistically, this will provide insight into possible
therapeutic targets for preventing injury or ameliorating fibrosis.
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MATERIALS AND METHODS
Reagents and Antibodies
The following antibodies were purchased from Cell Signaling (Beverly, MA) unless
otherwise noted: Cleaved Caspase 3 (#9664), C/EBP homologous protein (CHOP;
#2895), c-Jun N terminal kinases (JNK; #9258), p-JNK (#4668), transforming
growth factor β (TGF-β; #3712S), fibronectin (F3648, Sigma-Aldrich, St. Louis,
MO), phospho- Mothers against decapentaplegic homolog 3 (pSMAD3; #12747),
α-tubulin (Santa Cruz, Dallas, TX, SC-23948) and β-actin (Santa Cruz, SC-47778).
Cisplatin (P4394, Sigma Aldrich, St. Louis, MO) was used for experiments
comparing the effects of a high, single dose model (euthanized three days later)
with the new repeated dosing model. Pharmaceutical grade cisplatin (purchased
directly from the University of Louisville hospital pharmacy) was used for
experiments comparing the effects of single versus repeated injury from cisplatin.
Similar effects were observed for both sources of cisplatin.
Animals
FVB mice were purchased from The Jackson Laboratory (Bar Harbor, ME). All
mice were maintained on a 12-hour light/12-hour dark cycle and provided food and
water ad libitum. Animals were maintained under standard laboratory conditions.
All animal procedures were approved by the Institutional Animal Care and Use
Committee at the University of Louisville and followed the guidelines of the
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American Veterinary Medical Association. Cisplatin at 25 mg/kg in PBS (200
μL/animal) was administered by i.p. injection. Seventy-two hours after cisplatin
injection, these mice were euthanized. Another cohort of mice received either 7 or
9 mg/kg cisplatin in PBS administered by i.p. injection once a week for four weeks.
For these survival studies, mice were monitored for weight loss and signs of
discomfort/distress on a daily basis. Mice exhibiting a weight loss of 20% or more
total body weight or high levels of discomfort and stress were euthanized. Mice
that survived the course of treatment were sacrificed 72 h after the fourth injection
of cisplatin. Serum was prepared and stored at -80°C. The kidneys were flash
frozen in liquid nitrogen or fixed in 10 % neutral buffered formalin for histological
purposes.
Blood Urea Nitrogen (BUN) and Serum Creatinine (SCr) Determination
BUN (DIUR-500) and SCr (C7548-120) were determined using kits from Bioassay
Systems (Hayward, CA) and Point Scientific Inc. (Canton, MI), respectively
following the manufacturers’ instructions. For SCr, this specific assay kit employs
a two reagent enzymatic assay system to eliminate interference by endogenous
creatine and ascorbic acid.
Protein Quantification, Western Blot Analysis, and ELISAs
Homogenates were made from kidney cortex by homogenization in Cell Extraction
Buffer (10 mM Tris-HCl (pH 8.0), 150 mM NaCl,1 mM imidazole, 1 mM magnesium
acetate, 20 mM EGTA, 10 mM

β-mercaptoethanol) containing a Complete

Protease Inhibitor Cocktail Tablet and Phosphatase Inhibitor Cocktail Tablet
(Roche, Indianapolis, IN). Homogenates were centrifuged at 15,000 X g for 10
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minutes at 4° C. Supernatants were removed, vortexed, aliquoted, and stored at
-80°C until use. Protein concentrations were determined using Bradford Reagent
(Bio-Rad, Hercules CA). Kidney homogenate (40 μg) was separated on 4–12%
gradient tris-glycine-SDS polyacrylamide gels and transferred to PVDF
membranes that were blocked in 5% (w/v) dried milk in tris-buffered saline
containing 0.1% Tween-20 (TBST) for 15 minutes. Membranes were incubated
with 1:5000 dilutions of primary antibody overnight at 4°C. The next morning,
membranes were washed 3 times for 5 minutes each with TBST containing 5 %
(w/v) dried milk. After incubation for 1 hour at room temperature with secondary
antibodies conjugated with horseradish peroxidase (1:40,000 in TBST containing
1.25% (w/v) dried milk), membrane proteins were detected by chemiluminiscence
substrate. ELISAs for KIM-1 (DY1817, R&D systems, Minneapolis, MN) and NGAL
(DY1857 R&D Systems) were performed on the urine as directed by the
manufacturer.
Gene Expression
Total RNA was isolated using RNA-STAT 60 (TEL-TEST Inc., Friendswood, TX)
combined with mini bead-beater glass beads and a Mini Bead Beater machine
(Cole-Palmer, Vernon Hills, IL). Other than using the bead beater glass beads to
disrupt the tissue, the protocol provided by TEL-TEST was used. cDNA was made
from 1 µg of total RNA using High Capacity Reverse Transcriptase (Life
Technologies, Grand Island NY) following manufacturers’ instructions.

Gene

specific cDNAs were quantitated using real-time PCR using predesigned TaqMan
assays. Tumor necrosis factor-alpha (TNF-α, Mm00443258_m1), interleukin-6

21

(IL6; Mm00446190_m1), interleukin 1-beta (IL1 ; Mm0043228_m1), chemokine
ligand (c-x-c motif) 1 (CXCL1; Mm04207460_m1), monocyte chemotactic protein1

(MCP-1;

Mm00441242_m1),

plasminogen

activator

inhibitor-1

(PAI-1;

Mm00435860_m1), alpha- smooth muscle actin (α-SMA ; Mm1546133_m1), bone
morphogenetic protein-7 (BMP-7; Mm00432102_m1), collagen type 4a1; (
COL4a1; Mm01210125_m1), cyclin dependent kinase inhibitor 2a (Cdkn2a;
Mm00491449-m1), connective tissuse growth factor (CTGF; Mm01192932_g1),
collagen type 1a1 (Col1a1; Mm00801666_g1), and the normalization genes beta
2 microglobulin (B2M; Mm00437762_m1) and β-actin (Mm01205647-g1) were
purchased from Life Technologies (Grand Island NY) and used in combination with
2X Gene expression Master Mix (Life Technologies).
Histology
Kidney sections (5 microns thick) from cisplatin-treated and untreated animals
were stained with H&E and PAS, and the degree of morphologic changes was
determined by light microscopy in a blinded fashion by a renal pathologist. The
following measures were chosen as an indication of morphologic damage to the
kidney after treatment with vehicle or cisplatin: proximal tubular necrosis, loss of
brush border, proximal tubule degradation, tubular casts, presence of inflammatory
cells, and interstitial fibrosis These measures were evaluated on a scale from 0
to 4, which ranged from not present (0), mild (1), moderate (2), severe (3), and
very severe (4).
Immunohistochemistry
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Kidney sections (5 microns thick) were rehydrated in Histoclear followed by an
ethanol gradient. Antigen retrieval was performed in citric acid buffer pH 6.0 at
95°C in a steamer for 30 min. Endogenous peroxidases were inhibited with 3%
hydrogen peroxide and dual endogenous enzyme blocker (Dako, S2003) for 10
minutes, followed by two 5 minute PBS washes. Slides were then blocked with
avidin for 10 minutes followed by a PBS wash, and then biotin for 10 minutes
followed by another wash in PBS (Dako, X0590). Slides were further blocked with
5% normal goat serum in 0.1% TBST for 1 hour at room temperature. α-SMA
primary rabbit antibody (Abcam, ab5694) was added to slides at a concentration
of 0.5 µg/mL, and allowed to incubate at 4°C overnight.

Biotinylated goat anti-

rabbit IgG antibody (1:25000) (Vector laboratories, BA-1000) was added to each
section and incubated for 30 minutes at room temperature. Slides were rinsed
twice with PBS for 5 minutes each. Vector ABC reagent (Vector laboratories, PK7100) was added to each section and incubated for 30 minutes at room
temperature. Slides were rinsed 2 times with PBS for 5 minutes each, followed by
the addition of NovaRed Substrate to detect HRP (Vector Laboratories, SK-4800)
to each section for 5-7 minutes. Slides were rinsed in distilled water for 5 minutes,
counterstained with modified Mayer’s hematoxylin (Thermo-scientific, 72804), then
dehydrated in an ethanol gradient to Histoclear, followed by mounting with
Permount (Fisher Scientific, SP15). Positive staining for α-SMA was quantified
using Metamorph Image Analysis software, and percent positive pixels were
calculated as follows: (threshold area/(total area-acellular area)).
Sirius Red/ Fast Green Staining
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Kidney sections (5 microns thick) were rehydrated in Histoclear followed by an
ethanol gradient. Slides were then dipped into a Coplin jar containing PBS-T
(PBS+0.1% tween-20) and incubated for 5 minutes. Slides were washed with
distilled water twice for 5 minutes each and then incubated in saturated picric acid
(1.2% w/v, Ricca Chemicals; 5860-32) containing 0.1% Sirius Red (Sigma,
365548) and 0.1% Fast Green (Sigma, F7258). Slides were washed with 5%
glacial acetic water until water ran clear. Tissue samples were then dehydrated
and fixed using Permount (Fisher, F-SP15-100). Positive staining for Sirius Red
was quantified using Metamorph Image Analysis software, and percent positive
pixels were calculated as follows: (threshold area/(total area-acellular area)).
Statistical Analysis Data
Data are expressed as means ± SEM for all experiments. Multiple comparisons of
normally distributed data were analyzed by one-way ANOVA, as appropriate, and
group means were compared using Tukey post-tests. Single comparisons were
analyzed by Student’s t-test where appropriate. The criterion for statistical
differences was p < 0.05*, p<0.01** and p<0.001***. For statistical analysis of the
survival curve, Log-Rank (Mantel-Cox) test was used.
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RESULTS
Effects of dosing regimens on mouse survival. The current, standard model
used to study cisplatin-induced AKI does not allow for the analysis of long-term
effects on kidney function and physiology, nor does it recapitulate the repeated
dosing regimen of cisplatin patients receive in the clinic. We hypothesized that
administration of a low dose of cisplatin once a week for several weeks, which
better recapitulates the human dosing regimen, would improve mouse lifespan,
thus allowing for analysis of long-term effects on kidney function and physiology.
We compared survival of mice given a single high dose of cisplatin (standard
dosing model; 25 mg/kg) to mice given a dose of cisplatin (7 or 9 mg/kg) once a
week for 4 weeks. All mice subjected to the standard dosing regimen were
sacrificed three days after cisplatin injection due to moribund status. Mice treated
with the 7 mg/kg repeated dosing regimen survived the course of treatment and
were sacrificed 3 days after the fourth treatment (day 24). Ninety percent of mice
treated with a 9 mg/kg repeated dosing regimen survived until day 24 (Fig1). These
data indicate that the repeated dosing model with 7 mg/kg enables longer-term
survival of mice, and thus can be used for long-term studies of kidney function and
physiology.
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Effects of dosing regimens on kidney injury and function. In order to assess
the impact of repeated, low dosing of cisplatin on the kidney, we measured
markers of kidney function and injury in the serum and urine of mice, respectively.
Blood urea nitrogen (BUN) and serum creatinine (SCr) are standard measures of
kidney function as their levels increase in the blood when the filtering capacity of
the kidney is significantly reduced (69). BUN levels of mice treated with the
standard dosing model were significantly increased at 72 hours post-treatment
(Fig2A). In the repeated dosing model, BUN also increased, but not significantly
(Fig2A). SCr levels were significantly increased for both the repeated and standard
dosing models, but SCr levels were higher in the standard dosing model (Fig2A).
Kidney injury was evaluated by levels of urinary KIM-1 and NGAL, sensitive
biomarkers of AKI (70, 71). Urinary KIM-1 and NGAL levels were significantly
increased in the standard dosing model, but only NGAL levels were significantly
increased in the repeated dosing model, albeit to a lesser extent than in the
standard model (Fig 2B). These data indicate that the repeated dosing model of
cisplatin causes less loss of kidney function and less kidney injury than the
standard dosing model.

27

28

Effects of dosing regimen on inflammatory cytokine and chemokine levels.
One of the components of the standard dosing model of AKI is a large
inflammatory response. We compared the levels of inflammatory cytokines and
chemokines between the standard and repeated dosing models. TNFα is a
potent cytokine that mediates inflammatory tissue damage in the kidney, and
activates downstream cytokines and chemokines, particularly IL1-β, MCP-1, and
IL-6 (4, 72). CXCL1 plays a role in neutrophil recruitment to sites of tissue
inflammation (73). mRNA levels of Tnfα, Il1-β, Mcp-1, and Cxcl1 were increased
significantly and approximately to the same extent in both the standard and
repeated dosing models (Fig3A, C, D, E). Il-6 mRNA was significantly increased
in the standard dosing model, but only increased 5.51±2.01-fold in the repeated
dosing model (Fig3B). These data suggest similar effects of dosing on activation
of inflammatory cytokines and chemokines.
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Effect of dosing regimen on activation of ER stress and cell death proteins.
Cell death and ER stress are characteristic of cisplatin-induced AKI and
inhibiting/deleting key players in apoptosis protects the kidney from cisplatin in the
standard dosing model (7, 74, 75). Therefore, we assessed cellular markers of ER
stress and cell death proteins in both models. JNK phosphorylation and activation
is associated with ER stress-induced apoptosis and G2/M cell cycle arrest (15, 66).
We found that JNK was phosphorylated and activated in both models (Fig4).
CHOP is also associated with ER stress, and was also activated in both models
(Fig4) (76). However, cleaved caspase 3 (CC3), a marker of apoptosis, didn’t
show an increase in the repeated dosing model. (Fig4). These data suggest that
while both models show similar trends in activation of ER stress proteins, there is
less cell death activation in the repeated dosing model.
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Effect of dosing regimen evident in tissue pathology. The standard dosing
model of cisplatin-induced AKI is associated with changes in kidney pathology,
particularly with increased levels of tubular necrosis and loss of brush borders (21,
77). We compared kidney pathology of the standard and repeated dosing models
and examined tubular necrosis, loss of brush borders, tubule dilation, cast
formation, presence of inflammatory cells and interstitial fibrosis, all of which are
indicative of kidney injury and damage. Blinded analysis by a certified pathologist
indicated tubular necrosis was significantly higher in the standard dosing model,
compared to the repeated dosing model (Fig5A).

In contrast, there was a

significant loss of brush borders (Fig5B), an increase in tubular dilation (Fig5C),
and an increase in cast formation (Fig5D) in both models. Interestingly, only the
repeated dosing model displayed a significant increase in the presence of
inflammatory cells and interstitial fibrosis (Fig5E,F). These data demonstrate that
there are key differences in kidney pathology between the standard and repeated
dosing models.
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Fibrotic markers and fibrosis in the repeated dosing model. Since pathology
of kidney sections revealed tubulointerstitial fibrosis in the repeated dosing model,
we wanted to examine known markers of maladaptive repair involved in the
induction of fibrosis. TGF-β is released by immune cells in response to kidney
injury as a way to make conditions suitable for new epithelial cells to grow (22).
However, during maladaptive repair, dedifferentiated epithelial cells in a senescent
state can also release TGF- β, leading to fibrosis (21). TGF-β can signal through
its receptor to lead to phosphorylation of SMAD3, thereby activating pathways that
increase extracellular matrix protein deposition, particularly fibronectin (78, 79).
BMP-7 is also a member of the TGF-β superfamily and works to counteract the
profibrotic activity of TGF-β (80).

TGF-β, p-SMAD3, and fibronectin were all

increased at the protein level in the repeated dosing model (Fig6A). Bmp-7 mRNA
expression was significantly decreased (Fig6B).

Col1a1, which encodes for

collagen type I protein and is a transcript marker of fibrosis, also significantly
increased at the message level in the repeated dosing model (81)(Fig6B). PAI-1
is associated with maladaptive repair and is produced by resident and intrarenal
inflammatory cells and inhibits fibrinolysis, leading to the accumulation of scar
tissue in the kidney (82). Pai-1 mRNA expression was increased in the repeated
dosing model (Fig6B). Cdkn2a encodes for p16, and increased expression of
Cdkn2a is associated with maladaptive repair and cell cycle arrest at the G2/M
phase (66); Cdkn2a expression was significantly increased following repeated
dosing (Fig6B). Myofibroblast numbers increase during kidney fibrosis and are
responsible for synthesis of collagen (83, 84). These cells can be identified by
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their expression of α-SMA.

α-SMA IHC indicated increased numbers of

myofibroblasts following repeated dosing of cisplatin (Fig6D). Collagen deposition
as the result of extracellular matrix production can be quantified with Sirius red,
fast green staining (SR/FG) which stains collagen red. We performed SR/FG
staining and found that collagen levels increased in the kidneys following repeated
dosing of cisplatin (Fig6C). Taken together, these data indicate that there are
alterations in key mediators of kidney fibrosis in the repeated dosing model,
indicative of maladaptive repair. Furthermore, since fibrosis is the hallmark of
CKD, these data suggest that the ultimate outcome of our repeated, low dosing
cisplatin model is CKD.
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Comparison of a single, low dose of cisplatin (7VVV) to repeated dosing
model. To determine if fibrosis is a result of a single, low dose of cisplatin, or rather
repeated injury from several low doses, mice were administered a low dose of
cisplatin (7 mg/kg) followed by three weekly vehicle injections (7VVV) and
compared to mice receiving 4 weekly cisplatin injections (7777). BUN and SCr
both increased significantly in the repeated dosing model, but not following a single
low dose (Fig7A). Likewise, levels of Tnfα and Il6 mRNA expression increased
with repeated dosing (7777) of cisplatin, but not following a single dose (7VVV;
Fig7C). Western blot analysis of TGF-β and fibronectin in the kidney indicated that
a single dose was not sufficient to cause an increase in these fibrotic markers
(Fig7B). mRNA expression of Pai-1, Cdk2na, and Col1a1 did not increase, and
Bmp-7 mRNA levels did not decrease in the single, low dose regimen (Fig7C).
Quantification of SR/FG staining for collagen deposition and IHC staining for αSMA for myofibroblasts also indicated that a single low dose was insufficient to
elicit changes (Fig7D,E). These data suggest that fibrosis is a result of repeated
injury to the kidney by several low doses of cisplatin.
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DISCUSSION

The dosing regimen of cisplatin varies by cancer type as well as the ability
of the patient to handle prescribed doses. In lung cancer, for example, patients
receive 60-100 mg/m2 of cisplatin intravaneously every 21 days in conjunction with
other antineoplastic drugs, while patients with cervical cancer receive 40 mg/m2 of
cisplatin intravaneously once a week for six weeks in conjunction with radiation
therapy (85). Regardless, treatment of human cancers with cisplatin often leads
to a nephrotoxic effect that is cumulative and dependent on the dose of cisplatin
being administered. AKI occurs in some individuals even after one low dose of
cisplatin, and when AKI occurs, oncologists will dramatically lower the dose of
cisplatin used- usually decreasing the dose by 50-75% (85). As a result, this leads
to a less efficacious cancer treatment. Thus, the development of renoprotective
agents would greatly aid in allowing patients to receive the full dose of cisplatin for
a more efficacious treatment, while at the same time decreasing the likelihood of
an AKI event. This area of research has been ongoing for thirty or more years.
Unfortunately with the exception of amifostine, which is no longer used as a
renoprotective agent in the clinic, there are no renoprotective agents available and
none have succeeded in clinical trials. This is in opposition to the fact that many
renoprotective agents have been tested in rats and mice and have shown a
significant protective effect.
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Furthermore, it is established that multiple episodes of AKI can lead to CKD
(51). This is of importance as, until recently, it was widely held that patients who
suffer from an episode of AKI usually undergo full recovery. This is a biased view
as the standard measure of kidney function in the clinic is SCr, which is highly
unreliable and can only detect changes in function when there is fifty percent
nephron loss.
In an ideal situation, researchers would be able to study the long-term
effects of cisplatin-induced AKI in a model that recapitulates a dosing regimen
similar to what is used in humans- mainly the fact that patients receive multiple
doses of cisplatin over an extended period of time. Unfortunately, there are no
models to study this. Currently, the standard dosing model of cisplatin-induced
AKI has limitations that cannot be overcome for studying AKI to CKD progression.
For one, a single, high dose regimen is not clinically relevant.

Patients are

administered multiple low doses of cisplatin over an extended period of time.
Secondly, with the standard dosing model, mice cannot be aged out to study longterm effects associated with repeated AKI, namely fibrosis—the underlying
pathology of CKD (86). Furthermore, models of CKD, which often lead to fibrosis,
often are short term models that lead to this pathology within a week (i.e. UUO/ IR
models), and there no models of cisplatin-induced CKD. Here, we report a new
model for studying the nephrotoxic effects of cisplatin that mimics the repeated
administration of cisplatin given clinically, and allows for analysis of long-term
effects on kidney function. Data obtained from this model indicate that repeated
cisplatin injury induces interstitial fibrosis which is indicative of CKD, and suggests
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that targeting fibrotic mediators may prevent both short- and long-term renal sideeffects of cisplatin.
The standard dosing model of cisplatin induces high levels of kidney injury
and cell death through apoptosis and necrosis, which are processes known to be
involved in AKI (7). This in turn results in a rapid loss of kidney function. With the
repeated dosing model, cleaved caspase 3 as a measure of apoptosis is low, and
pathology reveals a low level of tubular necrosis. This coincides with lower injury
levels and a smaller decline in overall kidney function. These lower levels of injury
and the maintenance of kidney function with the repeated dosing model may be
key to explaining how mice treated with multiple low doses of cisplatin are able to
survive for 24 days, and beyond that.
As opposed to cell death, the repeated dosing model of cisplatin induces
interstitial fibrosis. Fibrosis is regarded as the result of maladaptive repair, which
is marked by prominent inflammation, G2/M cell cycle arrest leading to cellular
senescence, and the continual release of growth factors by epithelial cells that
ultimately culminate in fibrosis (21, 65, 66). While inflammation is also indicated
in AKI, it is associated with adaptive repair, and is usually short-lived.

In

maladaptive repair, however, inflammation persists and is marked by the inability
of M1 macrophages to become M2-type (36).

M1 macrophages are highly

associated with worsening of kidney injury, and thus suggests that the persistence
of this cell type is something that needs to be further examined within our model.
As far as inflammatory cytokines and chemokines, both models show a similar
activation of TNFα and its downstream targets, with the exception of IL6. In the
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repeated dosing model, IL6 was not significantly elevated. Although the role of IL6
in kidney injury is not well understood, it is correlated with onset and severity of
AKI, and has been indicated as a potential urinary and plasma biomarker of AKI
(87-89). The differential of IL6 elevation between a high injury model (standard AKI
model), and a low injury model (repeated dosing model) provides further validity of
the sensitivity of IL6.
In AKI, p21 and p53 play major roles in the adaptive processes after injury
(18, 22, 26, 90). p21 is responsible for cell cycle arrest before S phase, so that
damage to injured proximal tubule cells can be repaired before proceeding through
the cell cycle, while p53 mediates apoptosis (15, 22). These processes are pivotal
in removing injured epithelial and tubule cells, and also allowing for the growth of
new, fully functioning ones to restore kidney function. In maladaptive repair, p16
mediation leads to cellular senescence as opposed to apoptosis. This is mediated
by G2/M cell cycle arrest (65). Grgic et al. have shown in a model of diphtheria
toxin receptor expression on proximal tubule cells leading to PTC only injury, that
kidney function can be recovered after a single round of injury induced by
diphtheria toxin (65). In contrast, recurrent injury resulted in persistent
inflammation, cellular senescence, and G2/M cell cycle arrest of the tubule
epithelial cells, which led to maladaptive repair and interstitial fibrosis (65). G2/M
arrest and cellular senescence leading to maladaptive repair and fibrosis have also
been indicated in the ischemia-reperfusion and unilateral ureteral obstruction
mouse models (66). G2/M arrest is also associated with an increase in JNK
phosphorylation (66). However, JNK has also been indicated as a mediator of cell
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death as well. The increase in activated JNK (pJNK) observed in the repeated
dosing model did not correlate to cell death.

Instead, this increase in pJNK

suggests G2/M cell cycle arrest may be occurring. This is supported by the
increased expression of Cdk2na, a gene responsible for p16 (66). However, we
do not know if cellular senescence is occurring in epithelial cells in this model,
although there are increased levels of TGF-β and other pro-fibrotic cytokines which
are released by dedifferentiated epithelial cells in the senescent state (21). To
better determine if senescence is occurring, an assay for senescence-associated
beta-galactosidase needs to be performed.
In conclusion, we have found that fibrosis, not cell death, is the main
pathological outcome of our more clinically relevant repeated, low dosing cisplatin
model. Previously developed renoprotective agents that have fared well in animal
studies have focused on targeting cellular death pathways as a way to mediate
renal injury. These drugs include caspase inhibitors to block the initiation and
execution of apoptosis (91). Mice with caspase-1 deficiency are protected against
cisplatin-induced AKI due to blocking activation of proinflammatory cytokines IL1β, IL-18, and IL-6, suggesting that targeting caspases in humans may be
worthwhile (74). Furthermore, pifithrin-a, a p53 inhibitor, also decreases apoptosis
to preserve renal function during AKI (92). Since cell death is relatively low in our
model, it is likely that these therapies would not have a renoprotective effect in the
repeated dosing model of cisplatin. Our new model does provide several new
target pathways for the development of renoprotective agents. Our data suggest
that maladaptive repair processes are taking place in our model. Thus, potential
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therapeutics include targeting G2/M cell cycle arrest to stop the process of cellular
senescence and subsequent extended release of profibrotic cytokines.
Furthermore, studies on the role of the immune system need to be
performed. While the role of different immune cell types have been somewhat
defined in AKI models, very few studies have examined the role of these immune
cells in fibrotic processes, other than the role of macrophages (15, 31, 57). Thus,
understanding the mechanistic role of immune cells may provide better insight into
what types of cells to target to ameliorate fibrosis or protect from the development
of fibrosis, and lead to the potential development of immunotherapies for cisplatininduced kidney injury.
Furthermore, maladaptive repair processes are very similar to those
involved in normal aging. It is well documented that during aging, the kidney loses
function naturally and kidney structure changes (93-95).

Namely, aging is

associated with increased profibrotic markers, and age is a contributing factor to
number of deaths from CKD (95, 96). This suggests that aging plays an important
role in kidney injury and subsequent pathologies. In addition, cancer is regarded
as a disease associated with age, as there are approximately 4,750 per 100,000
patients who are 50 or older when diagnosed with cancer (97). This is especially
true for lung cancer patients as median age of diagnosis and of death is 70 and 72
respectively (97). Since lung cancer is the leading cause of cancer deaths in
Kentucky, this implies that improving on our current model by adding in factors
such as advanced age and lung cancer would provide a more comprehensive view
of cisplatin-induced nephrotoxicity, and potential interplay between kidney injury
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and lung cancer. This is of utmost importance as fibrosis and inflammation are
altered during aging and play a role not only in renal fibrosis, but also in cancer
development and metastasis (98).
In fact, recent studies have suggested the existence of a pulmonary-renal
syndrome in which inflammatory cytokines released by the lung during forms of
acute lung injury (ALI) may lead to the onset of AKI (99). Furthermore, the kidneys
may play a role in production and elimination of inflammatory mediators of ALI (99).
In animal models of kidney ischemia-reperfusion, Rabb et al. determined that there
were changes in gene expression of genes involved in pulmonary regulation of salt
and water handling in alveolar epithelial cells (100).

Furthermore, ischemia-

reperfusion models have also been associated with altered cytokine production in
the lung, showing increased levels of IL-1β, IL-6, and IL-12 in the lung (101). While
these studies were done in the context of ALI, it is known that cancer is a largely
inflammatory-mediated process (98).

Thus, it is feasible that inflammatory

changes occurring in the lungs may influence AKI and subsequent kidney disease
in humans, and that inflammatory processes associated with cisplatin-induced AKI
may have an effect on lung cancer.
Finally, the biggest advantage of our repeated low dosing model is that
comprehensive, temporal studies can be performed by looking at changes that
occur after each dose of cisplatin. We have shown that one dose at 7 mg/kg does
not have a long-term effect on renal outcome, but that four doses does. However,
we can now look at what happens at doses 2 and 3 as well to determine when
fibrosis starts occurring, and correlate this to when changes in kidney function and
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injury also start to change. Furthermore, we can perform immune cell studies at
each of these time points to determine when certain immune cell types are most
important.
Overall, our repeated, low dose cisplatin model of nephrotoxicity indicates
that fibrosis may be a more physiologically relevant process to target in humans
for the development of renoprotective or injury reversing agents. Not only are we
able to examine long-term outcomes of multiple doses of cisplatin, but our model
affords us the ability to go back and examine changes occurring temporally to
provide better mechanistic insight into when maladaptive repair processes are
taking place. Now that this model has been established, it is important to better
characterize the processes that occur during the injury phase.

This is of

importance as most nephrotoxic therapeutic agents have focused on amelioration
of injury, rather than protection against injury. By better understanding when and
how injury occurs, we can better target nephrotoxicity leading to AKI or CKD before
it happens.
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SUMMARY
Cisplatin is a chemotherapeutic used for the treatment of many cancers but
has nephrotoxic side effects leading to acute kidney injury (AKI). Thirty percent of
patients administered cisplatin will develop kidney injury, requiring the oncologist
to withhold or reduce the next dose, leading to a less effective therapeutic regimen.
Although recovery can occur after one episode of cisplatin-induced AKI,
longitudinal studies have indicated multiple episodes may lead to the development
of chronic kidney disease (CKD). Furthermore, the severity of AKI sustained is
also a predictor of CKD. CKD is an irreversible disease with no current treatments
that can progress to end-stage renal disease (ESRD), and eventual mortality.
Most of what is known about the complex pathophysiology of AKI has been
studied in animal models. The standard mouse model of cisplatin-induced AKI
consists of one, high dose of cisplatin (> 20 mg/kg) that is lethal to the animal three
days later. This model doesn’t accurately reflect the dosing regimen patients
receive (multiple doses over weeks or months), and doesn’t allow for long-term
studies to examine outcomes associated with CKD, particularly the development
of fibrosis. We have developed a repeated dosing model with administration of
cisplatin once a week for four weeks in mice. Comparison of this repeated dosing
model to the standard dosing model demonstrated that inflammatory cytokines and
chemokines were induced in the repeated dosing model, but levels of cell death
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were lower in the repeated dosing model.

The repeated dosing model had

increased levels of fibrotic markers (fibronectin, TGFβ, and α-SMA), and pathology
revealed that interstitial fibrosis was occurring. As fibrosis is the hallmark of CKD,
these data demonstrate that the repeated dosing model can be used to study AKI
to CKD progression.
With this newly established model, we hope to identify potential targets of
the fibrotic pathway for the development of renoprotective agents. In order to do
so, we need to better understand the mechanism by which AKI can progress to
CKD.

Planned future studies include examining immune cell populations at

various time points to determine the temporal role of immune cells during this
transitional process.

Furthermore, we can also use this model to measure

temporal changes in both kidney injury and function to better determine key points
in the injury phase that are important to target for the development of
renoprotective agents.
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LIST OF ABBREVIATIONS
AKI: acute kidney injury
CKD: chronic kidney disease
RIFLE: risk injury failure loss end-stage kidney disease
GFR: glomerular filtration rate
SCr: serum creatinine
Ctr1: copper transporter 1
OCT2: organic cation transporter 2
BCL2: B cell CLL/ lymphoma 2
BAX: BCL2-associated X protein
PUMA-α: p53 upregulated modulator of apoptosis
ATN: acute tubular necrosis
Cdks: cyclin dependent kinases
CIP/KIP: Cdk interacting protein/ kinase inhibitory protein
INK4: inhibitor of cyclin-dependent kinase 4
PCNA: proliferating cell nuclear antigen
BrdU: bromodeoxyuridine
ER (Stress): endoplasmic reticulum (stress)
MMPs: matrix metalloproteinases
UUO: unilateral ureteral obstruction
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IR: ischemia reperfusion
LLC-PK1: Lilly laboratories porcine kidney 1 cells
IL-10: interleukin-10
TNFα: tumor necrosis factor alpha
FasL: Fas ligand
Tim-1: T-cell immunoglobulin and mucin domain-1
(p)SMAD3: (phospho) mothers against decapentaplegic 3
TGFβ-(1): transforming growth factor beta- (1)
Col1a1: collagen type 1a1
CHOP: CCAAT/enhancer-binding protein homologous protein
(p)JNK: c-JUN N-terminal kinase
BUN: blood urea nitrogen
IL6: interleukin 6
IL1-β: interleukin 1-beta
CXCL1: chemokine (C-X-C motif) ligand 1
MCP1: monocyte chemotactic protein 1
PAI-1: plasminogen activator inhibitorα-SMA: alpha-smooth muscle actin
BMP-7: bone morphogenetic protein-7
Cdkn2a: cyclin-dependent kinase inhibitor 2a
CTGF: connective tissue growth factor
B2M: beta-2 microglobulin
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SR/FG: sirius red/ fast green
KIM-1: kidney injury molecule-1 (see also Tim-1)
NGAL: neutrophil-gelatinase associated protein
CC3: cleaved caspase 3
ALI: acute lung injury
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